(Q38059027)

27 August 2017

title

Cost-effectiveness and economic benefits of vaccines in low- and middle-income countries: a systematic review (English)

1 reference

27 August 2017

1

Sachiko Ozawa

1 reference

27 August 2017

Andrew Mirelman

2

1 reference

27 August 2017

Meghan L Stack

series ordinal

3

1 reference

27 August 2017

Damian G Walker

series ordinal

4

1 reference

27 August 2017

Orin S Levine

series ordinal

5

1 reference

27 August 2017

language of work or name

English

0 references

publication date

8 November 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

31

1 reference

27 August 2017

issue

1

1 reference

27 August 2017

page(s)

96-108

1 reference

Herd immunity and herd effect: new insights and definitions

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

The value of vaccination: a global perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

The societal value of vaccination in developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

The Decade of Vaccines Collaboration: developing a global roadmap for saving lives.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Rethinking the benefits and costs of childhood vaccination: the example of the Haemophilus influenzae type b vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Cost-effectiveness of measles elimination in Latin America and the Caribbean: a prospective analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Economic evaluation of delivering Haemophilus influenzae type b vaccine in routine immunization services in Kenya

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Modeling the impact of a partially effective HIV vaccine on HIV infection and death among women and infants in South Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Outbreaks of influenza A among nonvaccinated healthcare workers: implications for resource-limited settings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

The impact of immunization on the association between poverty and child survival: Evidence from Kassena-Nankana District of northern Ghana

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

The cost-effectiveness of rotavirus vaccination in Malawi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Modeling the economic benefits of an AIDS vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Economic evaluation of Haemophilus influenzae type B vaccination in Indonesia: a cost-effectiveness analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Rotavirus vaccination in northeast Brazil: A laudable intervention, but can it lead to cost-savings?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Cost-effectiveness of rotavirus vaccination in peru

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Economic impact of a rotavirus vaccination program in Mexico.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Economic impact of pneumococcal conjugate vaccination in Brazil, Chile, and Uruguay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Using private demand studies to calculate socially optimal vaccine subsidies in developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Cost-effectiveness of three different vaccination strategies against measles in Zambian children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Potential epidemiological and economical impact of two rotavirus vaccines in Colombia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Cost-effectiveness analysis of routine rotavirus vaccination in Brazil.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Economic analysis of the global polio eradication initiative.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Cost effectiveness analysis of strategies for child health in developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Rotavirus diarrhea disease burden in Peru: the need for a rotavirus vaccine and its potential cost savings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Costs of diarrheal disease and the cost-effectiveness of a rotavirus vaccination program in kyrgyzstan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Vaccine-preventable haemophilus influenza type B disease burden and cost-effectiveness of infant vaccination in Indonesia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Cost-effectiveness of the CRM-based 7-valent pneumococcal conjugated vaccine (PCV7) in Argentina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Cost-effectiveness of HPV 16, 18 vaccination in Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

The cost-effectiveness of alternative polio immunization policies in South Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

The cost-effectiveness of introducing hepatitis B vaccine into infant immunization services in Mozambique.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Comparison of four contingent valuation methods to estimate the economic value of a pneumococcal vaccine in Bangladesh

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Cost-effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Rotavirus disease in Uzbekistan: cost-effectiveness of a new vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Private demand for cholera vaccines in rural Matlab, Bangladesh

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Cost-effectiveness of new-generation oral cholera vaccines: a multisite analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Cost-benefit comparisons of investments in improved water supply and cholera vaccination programs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Economics of polio vaccination in the post-eradication era: should OPV-using countries adopt IPV?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Cost-effectiveness of Rotavirus vaccination in Vietnam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Economic evaluation of pneumococcal conjugate vaccination in The Gambia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Health and economic impact of rotavirus vaccination in GAVI-eligible countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

The cost-effectiveness of universal vaccination of children against hepatitis A in Argentina: results of a dynamic health-economic analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Private demand for cholera vaccines in Beira, Mozambique

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Cost-effectiveness analysis of a hypothetical hepatitis C vaccine compared to antiviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Low-cost interventions accelerate epidemiological transition in Upper East Ghana

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Cost-benefit analysis of a rotavirus immunization program in the Arab Republic of Egypt

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

The demand for a dengue vaccine: a contingent valuation survey in Metro Manila

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Comparison of cost-effectiveness of preventive and reactive mass immunization campaigns against meningococcal meningitis in West Africa: a theoretical modeling analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Economic evaluation of Haemophilus influenzae type b vaccination in Moscow, Russian Federation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Projected cost-effectiveness of rotavirus vaccination for children in Asia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Crucial factors that influence cost-effectiveness of universal hepatitis B immunization in India

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Willingness to pay for hypothetical malaria vaccines in rural Burkina Faso

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

The cost of influenza in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Cost-effectiveness of pneumococcal conjugate vaccination in Latin America and the Caribbean: a regional analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Rotavirus disease burden and impact and cost-effectiveness of a rotavirus vaccination program in kenya

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Predicting the cost-effectiveness of introducing a pre-erythrocytic malaria vaccine into the expanded program on immunization in Tanzania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Eradication versus control for poliomyelitis: an economic analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

A cost-effectiveness analysis of Japanese encephalitis vaccine in Cambodia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Willingness to pay for three hypothetical malaria vaccines in Nigeria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Economic analysis of the 1996-1997 mass measles immunization campaigns in South Africa.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Cost-effectiveness of introducing a rotavirus vaccine in developing countries: the case of Mexico

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Cost-effectiveness analysis of universal childhood vaccination against varicella in Brazil.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Cost-effectiveness of universal childhood hepatitis A vaccination in Chile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Estimating the cost-effectiveness of pneumococcal conjugate vaccination in Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Potential cost-effectiveness of a rotavirus immunization program in rural China

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Private demand for a HIV/AIDS vaccine: evidence from Guadalajara, Mexico

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Household demand for preventive HIV/AIDS vaccines in Thailand: do husbands' and wives' preferences differ?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Rethinking Cholera and Typhoid Vaccination Policies for the Poor: Private Demand in Kolkata, India

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Economic evaluation of a routine rotavirus vaccination programme in Indonesia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

A cost-effectiveness analysis of universal childhood hepatitis A vaccination in China

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

During the 'decade of vaccines,' the lives of 6.4 million children valued at $231 billion could be saved.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

Estimated economic benefits during the 'decade of vaccines' include treatment savings, gains in labor productivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.103

10.1016/J.VACCINE.2012.10.103

7 January 2021

Identifiers

DOI

1 reference

27 August 2017

1 reference